A Retrospective Analysis of Health Care Costs for Bone Fractures in Women with Early-stage Breast Carcinoma
Overview
Affiliations
Background: In this retrospective data base study, the authors sought to estimate direct costs for bone fractures in women age > or =65 years with early-stage breast carcinoma and to compare those costs with treatment costs for bone fractures in older women without early-stage breast carcinoma.
Methods: Direct costs for bone fractures in patients with early-stage breast carcinoma, which consist of excess treatment costs for bone fracture and excess costs of long-term care for bone fracture, were evaluated by using the 1997-1998 Standard Analytical File. The statistical significance of the difference in inpatient costs, medical treatment costs, and long-term care admission rates were determined with the t test and the Fisher chi-square test, respectively.
Results: For older women with early-stage breast carcinoma, the direct costs for bone fracture were estimated at $45,579, and 57% of those costs came from treating the bone fracture (32% came from inpatient hospital costs, and 25% came from noninpatient hospital costs), 25% came from other excess treatment costs, and 18% came from excess long-term care costs. The women who had early-stage breast carcinoma and sustained bone fracture did not differ significantly from the women without early-stage breast carcinoma who sustained a bone fracture.
Conclusions: Bone fracture was associated with high direct costs in older women with early-stage breast carcinoma. Additional research should include appropriate, incidence-based studies to investigate the potential benefit of an intervention for preventing bone fracture in this increasingly large patient population.
Radiographic anatomy of the proximal femur: femoral neck fracture transtrochanteric fracture.
Lima A, Miranda S, Vasconcelos H Rev Bras Ortop. 2017; 52(6):651-657.
PMID: 29234647 PMC: 5720858. DOI: 10.1016/j.rboe.2017.10.007.
Fracture risk predictions based on statistical shape and density modeling of the proximal femur.
Bredbenner T, Mason R, Havill L, Orwoll E, Nicolella D J Bone Miner Res. 2014; 29(9):2090-100.
PMID: 24692132 PMC: 4357175. DOI: 10.1002/jbmr.2241.
Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid.
Aft R Int J Womens Health. 2012; 4:569-76.
PMID: 23152708 PMC: 3496531. DOI: 10.2147/IJWH.S29101.
Winters-Stone K, Dobek J, Nail L, Bennett J, Leo M, Naik A Breast Cancer Res Treat. 2011; 127(2):447-56.
PMID: 21424279 PMC: 3124708. DOI: 10.1007/s10549-011-1444-z.
Safety of aromatase inhibitors in the adjuvant setting.
Perez E Breast Cancer Res Treat. 2007; 105 Suppl 1:75-89.
PMID: 17912638 PMC: 2001222. DOI: 10.1007/s10549-007-9704-7.